The Effect of Losartan Versus Amlodipine-based Therapy in Ischemic Stroke (0954-338)(COMPLETED)
|ClinicalTrials.gov Identifier: NCT00754429|
Recruitment Status : Completed
First Posted : September 18, 2008
Last Update Posted : October 23, 2013
|Condition or disease||Intervention/treatment||Phase|
|Ischemic Stroke||Drug: losartan Drug: amlodipine||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Effect of Losartan Versus Amlodipine-based Antihypertensive Therapy on Atherosclerotic Inflammatory Markers and Cerebrovascular Regulation in Ischemic Stroke Patients|
|Study Start Date :||June 2004|
|Actual Primary Completion Date :||June 2009|
|Actual Study Completion Date :||July 2009|
Losartan 50mg qd for 30 weeks, if blood pressure > 140/90, or mean arterial Bp ≧ 15% of baseline, then add on diuretics.
losartan 50mg qd for 30 weeks.
Active Comparator: B
Amlodipine 5 mg q.d for 30 weeks, if blood pressure > 140/90, or mean arterial Bp ≧ 15% of baseline, then add on diuretics.
amlodipine 5 mg q.d for 30 weeks.
Other Name: Norvasc
- MCAFV and TCD for measuring cerebral autoregulatory indices at week 0, week 6, week 18 and week 30. [ Time Frame: At week 0, week 6, week 18 and week 30. ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00754429
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|